|
業務類別
|
Biotechnology |
|
業務概覽
|
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T. |
| 公司地址
| 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080 |
| 電話號碼
| +1 415 910-5717 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.quincetx.com |
| 員工數量
| 38 |
| Mr. Brendan Hannah |
Chief Operating Officer, Chief Compliance Officer and Chief Business Officer |
美元 453.75K |
27/04/2026 |
| Dr. Charles S. Ryan, J.D.,PhD |
President |
美元 500.00K |
27/04/2026 |
| Dr. Dirk Thye, M.D. |
Chief Executive Officer, Chief Medical Officer and Director |
美元 550.00K |
27/04/2026 |
|
|
| Ms. June Bray |
Independent Director |
22/04/2026 |
| Mr. Christopher J. Senner |
Independent Director |
27/04/2026 |
| Dr. Dirk Thye, M.D. |
Chief Executive Officer, Chief Medical Officer and Director |
27/04/2026 |
| Mr. David A. Lamond |
Chairman of the Board |
27/04/2026 |
|
|
|
|
